SCHEMBL2538534

SCHEMBL2538534

Cc1ccc(/C=C2\SC(=O)NC2=O)c(C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 4/20 0.57
PIM2 Q9P1W9 3/20 0.57
HPGD P15428 1/20 0.57
POLB P06746 3/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
TDP1 Q9NUW8 2/20 0.53
KDM4E B2RXH2 1/20 0.53
NSD2 O96028 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
MAPK1 P28482 1/20 0.53
RECQL P46063 1/20 0.53
GFER P55789 1/20 0.53
MCL1 Q07820 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TTR P02766 1/20 0.52
PTPN1 P18031 2/20 0.51
GSK3B P49841 1/20 0.51
IGF1R P08069 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1249961 0.81 TTR (0.68) PIM1PIM2HPGDPOLBNPC1
SCHEMBL1249962 0.81 TTR (0.68) PIM1PIM2HPGDPOLBNPC1
SCHEMBL6929414 0.80 TDP1 (0.74) PIM1PIM2HPGDPOLBRAB9A
SCHEMBL6929411 0.80 TDP1 (0.74) PIM1PIM2HPGDPOLBRAB9A
SCHEMBL2545594 0.74 PIM1 (1.00) PIM1PIM2HPGDNPC1RAB9A
SCHEMBL2545596 0.74 PIM1 (1.00) PIM1PIM2HPGDNPC1RAB9A
SCHEMBL2547566 0.74 PIM1 (1.00) PIM1PIM2HPGDNPC1RAB9A
SCHEMBL7459355 0.74 PIM1 (0.71) PIM1PIM2HPGDGSK3BIGF1R
SCHEMBL7459357 0.74 PIM1 (0.71) PIM1PIM2HPGDGSK3BIGF1R
SCHEMBL2539676 0.73 PIM1 (1.00) PIM1PIM2HPGDTTRGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US claimed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 EP claimed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 WO claimed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885HPGD 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.